In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Hold rating on Onconova Therapeutics (ONTX). The company’s shares closed last Thursday at $0.29, close to its 52-week low of $0.10.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 25.5% and a 54.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Onconova Therapeutics is a Hold with an average price target of $0.30.
See today’s analyst top recommended stocks >>
Onconova Therapeutics’ market cap is currently $53.57M and has a P/E ratio of 0.90. The company has a Price to Book ratio of 3.21.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ONTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.
